Fate Therapeutics, Inc. (FATE)

Fate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	41.25	36.06	41.87	61.33	133.58	167.35
Short-Term Investments	181.58	243.01	273.31	374.89	482.33	315.57
Cash & Short-Term Investments	222.83	279.07	315.18	436.23	615.91	482.92
Cash Growth	-26.91%	-11.46%	-27.75%	-29.17%	27.54%	118.09%
Accounts Receivable	1.4	3.54	1.83	38.48	8.68	5.52
Other Receivables	2	2.1	0.9	0.8	1.1	1.5
Receivables	3.4	5.64	2.73	39.28	9.78	7.02
Prepaid Expenses	4.17	7.2	13.64	26.57	7.73	4.39
Total Current Assets	230.4	291.91	331.54	502.07	633.41	494.32
Property, Plant & Equipment	104.91	110.89	158.51	176.09	162.25	99.39
Long-Term Investments	26.1	27.66	0.98	4.94	100.66	-
Long-Term Deferred Charges	-	-	-	7.2	9.87	13.51
Other Long-Term Assets	10.23	10.24	15.19	15.26	15.26	15.24
Total Assets	371.63	440.69	506.22	705.56	921.46	622.46
Accounts Payable	4.04	9.37	4.72	8.27	8.61	6.28
Accrued Expenses	18.18	21.35	27.51	53.93	42.41	15.56
Current Portion of Leases	5.66	7.42	6.18	5.63	5.58	3.36
Current Unearned Revenue	-	0.39	0.69	42.23	21.48	21.14
Other Current Liabilities	0.8	-	-	4	3.2	39.22
Total Current Liabilities	28.67	38.52	39.09	114.05	81.28	85.56
Long-Term Leases	75.68	77.85	97.36	103.71	109.24	93.94
Long-Term Unearned Revenue	-	-	-	-	27.12	46.02
Other Long-Term Liabilities	5.92	5.6	1.35	3.86	24.97	12.48
Total Liabilities	110.27	121.97	137.8	221.62	242.62	238.01
Common Stock	0.12	0.11	0.1	0.1	0.1	0.09
Additional Paid-In Capital	1,731	1,716	1,580	1,536	1,449	941.22
Retained Earnings	-1,470	-1,398	-1,212	-1,051	-769.08	-556.93
Comprehensive Income & Other	0.06	0.27	0.02	-1.85	-0.76	0.07
Total Common Equity	261.36	318.72	368.41	483.94	678.84	384.44
Shareholders' Equity	261.36	318.73	368.42	483.94	678.84	384.45
Total Liabilities & Equity	371.63	440.69	506.22	705.56	921.46	622.46
Total Debt	81.33	85.27	103.54	109.34	114.82	97.3
Net Cash (Debt)	141.5	193.8	211.64	326.89	501.09	385.62
Net Cash Growth	-30.75%	-8.43%	-35.26%	-34.77%	29.95%	98.26%
Net Cash Per Share	1.20	1.70	2.15	3.38	5.29	4.68
Filing Date Shares Outstanding	115.33	114.6	99.24	98.16	96.43	93.78
Total Common Shares Outstanding	114.66	113.93	98.63	97.29	95.73	87.72
Working Capital	201.72	253.39	292.45	388.02	552.13	408.76
Book Value Per Share	2.28	2.80	3.74	4.97	7.09	4.38
Tangible Book Value	261.36	318.72	368.41	483.94	678.84	384.44
Tangible Book Value Per Share	2.28	2.80	3.74	4.97	7.09	4.38
Machinery	-	38.85	83.29	81.5	53.63	22.25
Construction In Progress	-	-	-	-	-	18.19
Leasehold Improvements	-	59.49	59.04	56.78	52.95	2.7

Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q